transient impairment of glucose tolerance is possible, particularly in individuals with pre-existing insulin resistance Injection site reactions: Mild and typically localised Contraindications include active malignancy (GH-IGF-1 signalling can promote tumour growth), pituitary-dependent conditions, pregnancy, and active diabetic retinopathy
The research, published in JAMA Psychiatry, provides reassurance that use of GLP1-RAs, such as semaglutide, are not associated with any increased risk of psychiatric adverse events or worsening of depressive symptoms
Piezo1 expression in neutrophils regulates shear-induced NETosis
Most of the samples (11 of 15
Participants receiving 2.4 mg weekly semaglutide lost an average of 15.3% of body weight over 68 weeks, with improvements in blood sugar control and cardiovascular risk factors